Tumor Biology

, Volume 31, Issue 2, pp 69–77 | Cite as

In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cancer cell lines

  • Yogesh Kumar
  • Sybille Mazurek
  • Shiyu Yang
  • Klaus Failing
  • Marc Winslet
  • Barry Fuller
  • Brian R. Davidson
Research Article


In tumour cells, the tetramer/dimer ratio of the pyruvate kinase isoenzyme type M2 (M2-PK) determines whether glucose carbons are degraded to lactate with production of energy (tetrameric form) or are channelled into synthetic processes (dimeric form). The influence of different tumour microenvironment conditions on the tetramer/dimer ratio of M2-PK and cell doublings were investigated in a non-metastatic and metastatic pancreatic cancer cell line. The metastatic Colo357 cells contained about fourfold more M2-PK protein and about 3.5-fold more dimeric M2-PK than the non-metastatic Panc-1 cells. In Colo357 cells hypoxia, glucose starvation as well as acidification induced an increase of the dimeric form of M2-PK, whereas in Panc-1 cells no effect on M2-PK was observed. Under hypoxia in Colo357 cells, the dimerization and inactivation of M2-PK results in an inhibition of cell proliferation, whereas under glucose starvation and acidification the dimerization of M2-PK allowed further cell doublings. M2-PK expression and the quaternary structure of M2-PK are influenced by the tumour metastatic potential. The quaternary structure of M2-PK may be differently affected by hypoxia, glucose starvation and acidification with severe consequences on cell doublings.


pyruvate kinase M2 Tumour M2-PK Tumour microenvironment Pancreatic cancer 


  1. 1.
    Warburg O, Poesener K, Negelein E. Über den Stoffwechsel der Tumoren. Biochem Z. 1924;152:319–44.Google Scholar
  2. 2.
    Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Board M, Humm S, Newsholme EA. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J. 1990;265:503–9.PubMedGoogle Scholar
  4. 4.
    Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Cerwenka H, Aigner R, Bacher H, Werkgartner G, el Shabrawi A, Quehenberger F, et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res. 1999;19:849–51.PubMedGoogle Scholar
  7. 7.
    Kumar Y, Gurusamy K, Pamecha V, Davidson BR. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Pancreas. 2007;35:114–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Novotny I, Dite P, Dastych M, Zakova A, Trna J, Novotna H, et al. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer. Hepatogastroenterology. 2008;55:1475–7.PubMedGoogle Scholar
  9. 9.
    Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci. 2004;49:1149–55.CrossRefPubMedGoogle Scholar
  10. 10.
    Mazurek S, Luftner D, Wechsel HW, Schneider J, Eigenbrodt E. Tumour M2-PK: a marker of the tumour metabolome. In: Diamandis E, Fritsche H, Lilja H, Chan DW, Schwartz M, editors. Tumour markers: physiology,pathobiology, technology and clinical applications. Washington DC: AACC Press; 2002. p. 471–5.Google Scholar
  11. 11.
    Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol. 2007;19:265–76.CrossRefPubMedGoogle Scholar
  12. 12.
    Ashizawa K, Willingham MC, Liang CM, Cheng SY. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1, 6-bisphosphate. J Biol Chem. 1991;266:16842–6.PubMedGoogle Scholar
  13. 13.
    Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser WF, Hoves S, Andreesen R. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 2006 Mar 1;107:2013-21.Google Scholar
  14. 14.
    Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–65.PubMedGoogle Scholar
  15. 15.
    Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol. 2002;13:29–37.CrossRefPubMedGoogle Scholar
  16. 16.
    Ranniger K, Saldino RM. Arteriographic diagnosis of pancreatic lesions. Radiology. 1966;86:470–4.PubMedGoogle Scholar
  17. 17.
    Cuvier C, Jang A, Hill RP. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis. 1997;15:19–25.CrossRefPubMedGoogle Scholar
  18. 18.
    Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M, et al. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res. 2007;67:3345–55.CrossRefPubMedGoogle Scholar
  19. 19.
    Dixon WJ, editor. BMDP Statistical software manual. Berkeley, Los Angeles: Oxford University of California Press; 1992.Google Scholar
  20. 20.
    Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer. 1975;15:741–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, Gordon SG. Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. Int J Cancer. 1980;25:591–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Ding SJ, Li Y, Shao XX, Zhou H, Zeng R, Tang ZY, et al. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics. 2004;4:982–94.CrossRefPubMedGoogle Scholar
  23. 23.
    Dickson RB, Bates SE, McManaway ME, Lippman ME. Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res. 1986;46:1707–13.PubMedGoogle Scholar
  24. 24.
    Mazurek S, Michel A, Eigenbrodt E. Effect of extracellular AMP on cell proliferation and metabolism of breast cancer cell lines with high and low glycolytic rates. J Biol Chem. 1997;272:4941–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Webb SD, Sherratt JA, Fish RG. Mathematical modelling of tumour acidity: regulation of intracellular pH. J Theor Biol. 1999;196:237–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–43.CrossRefPubMedGoogle Scholar
  27. 27.
    Wike-Hooley JL, van den Berg AP, van der ZJ, Reinhold HS. Human tumour pH and its variation. Eur J Cancer Clin Oncol. 1985;21:785–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Park HJ, Lyons JC, Ohtsubo T, Song CW. Acidic environment causes apoptosis by increasing caspase activity. Br J Cancer. 1999;80:1892–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene. 1999;18:3199–204.CrossRefPubMedGoogle Scholar
  30. 30.
    Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. 2004;64:985–93.CrossRefPubMedGoogle Scholar
  31. 31.
    Shimizu T, Uehara T, Nomura Y. Possible involvement of pyruvate kinase in acquisition of tolerance to hypoxic stress in glial cells. J Neurochem. 2004;91:167–75.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Yogesh Kumar
    • 1
  • Sybille Mazurek
    • 2
    • 3
  • Shiyu Yang
    • 1
  • Klaus Failing
    • 4
  • Marc Winslet
    • 1
  • Barry Fuller
    • 1
  • Brian R. Davidson
    • 1
  1. 1.University Department of SurgeryRoyal Free and University College Medical School of UCLLondonUK
  2. 2.Institute of Biochemistry and Endocrinology, Veterinary FacultyUniversity of GiessenGiessenGermany
  3. 3.ScheBo Biotech AGGiessenGermany
  4. 4.Unit of Biomathematics, Veterinary FacultyUniversity of GiessenGiessenGermany

Personalised recommendations